All News
Day 4 EULAR Report
The last day in London was exciting as both the Late-Breaking abstracts and new EULAR guidelines were presented.
Read Article
Who does better in active #RA
b/tsDMARD naive?
Pt choice TNFi or JAKi
OR
Pt randomized to
TNFI or JAKi?
Strangely or not
PT choice did better
✅with satisfaction ~maybe expected
✅better retention on chosen #Rx
🤔unexpected
another arm in #RCTS?”
#EULAR2026 @RheumNow
OP0204 https://t.co/7qx5Rqq6a7
Links:
Janet Pope Janetbirdope ( View Tweet)
Can you step down #belimumab
In well controlled #SLE without flaring?
N=22 on #BEL eligible of 152
Able to taper if
REM >6/12
No #steroids
Normal C3,C4
Neg #antiDNA
Remission maintained in pts who reduced dose
6/22 didn’t flare OFF Rx
✅nice
#POS1052 #EULAR2026
@RheumNow https://t.co/IEyfRtTGfT
Links:
Janet Pope Janetbirdope ( View Tweet)
A bridge to uncertainty?
large #RCT of #baricitinib V #TNFi
In
Active #RA w #DVT/#VTE risk factor(s)
Sl more VTE, #infection #SIE on #Bar
NO increase #MACE
Sl ⬆️#malignancy
#VTE rate exceeded upper limit of a priori #CI
So is this good news or not?
#LB0009 @RheumNow #EULAR2026 https://t.co/CIfU7TL2TE
Janet Pope Janetbirdope ( View Tweet)
#EULAR2026 Want to catch up with the latest breakthrough in research on the last day of the conference? Please find our Day 4 Daily Recap led by @RheumNow and joined by my colleagues @synovialjoints @DrMiniDey 😃
https://t.co/fONe6g4ne1 https://t.co/kOqzF8t64w
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#EULAR2026 Please find my video on deep tissue depletion and associated histological remission following treatment with Obinutuzumab in #lupus nephritis @RheumNow
https://t.co/V9CNdPsLcV https://t.co/WLVFyaSSUE
Links:
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
RheumNow’s expanded coverage of the #EULAR2026 Annual Meeting is sponsored by Bristol Myers Squibb and UCB. RheumNow and its faculty independently select all coverage content.
Dr. John Cush RheumNow ( View Tweet)
This study evaluated the risk of flares after sustained drug-free rem in SLE.
% of pts w/ reported flares w/n yrs in rem:
48.6% at 2yrs
42.3% at 3yrs
35.2% at 5 yrs
Mucocut, msk, renal & immuno - ⬆️affected domain
Reassess pts regularly.
POS1354 @RheumNow #EULAR2026 https://t.co/DG0yNOW1nh
sheila RHEUMarampa ( View Tweet)
@RheumNow article further exploring the roe of lung ultrasound for RA-ILD screening as shown through 3 #EULAR2026 abstracts
https://t.co/smN8hg51nj
Jiha Lee JihaRheum ( View Tweet)
🏠 Take Home Messages from the early #axSpA session
🔺 Earlier diagnosis is possible and better
🔺 Early axSpA is not synonymous to mild
🔺 Longitudinally, early axSpA is heterogeneous
🔺 MRI has transformed the field
❗️Beware of pitfalls
#EULAR2026 @RheumNow https://t.co/IhGQSxssyd
Links:
Nelly ZIADE 🍀 Nellziade ( View Tweet)
Some new #vaccination #recommendations
#EULAR2026
@RheumNow https://t.co/j7cOJPpOcV https://t.co/VnGkFwTZ86
Links:
Janet Pope Janetbirdope ( View Tweet)
Remember
Babies of pts on chronic #immunosuppression with #SARDs
❎delay #vaccinations til 6/12
For safety & to mount sufficient response
#rotovirus #vaccine is Ok before 6 months or vaccine is ineffective
Pts w #SARDs need #COVID shots
@RheumNow #EULAR2026 #vaccine #recom https://t.co/WEzNajWlxY
Links:
Janet Pope Janetbirdope ( View Tweet)
What’s new with the 2026 update of reco for vax in AIIRD?
Vaccinate as soon as possible
Non-live vaccines are safe
Hold MTX for upto 2wks to inc vax yield
Strong reco for RZV
Catch-up vax for HPV in SLE
Rotavirus vax for newborns exposed in utero to TNFi
@RheumNow #EULAR2026 https://t.co/RZbyvAcYRI
Links:
sheila RHEUMarampa ( View Tweet)
#EULAR2026 #SARD #vaccination #recommendations
I think 🤔
✅proactive➡️take responsibility
✅close gap
✅mostly practical
But
How long will #shingrix work if #vaccine
In age<50yrs
When if ever
To revaccinate?
@RheumNow @eular_org @ACRheum https://t.co/najJwzdecL
Links:
Janet Pope Janetbirdope ( View Tweet)
#OP0156 #EULAR2026 FT839, CART therapy targeting CD19 & CD38, showed potent depletion of pathogenic B cells, plasmablasts/plasma cells & activated T cells, w/o conditioning chemotherapy. Data suggest potentially more accessible CART approach across autoimmune diseases. @RheumNow https://t.co/9COyXbghkl
Mrinalini Dey DrMiniDey ( View Tweet)
Updated SLR on D2T #RA (131 studies): JAKi maintain ACR20 even after 2-3 prior bDMARDs, with UPA outperforming ABA in head-to-head. But evidence on non-pharmacologic strategies in D2T RA remains nearly absent. Clear gap for future trials. @RheumNow #EULAR2026 POS1246
Jiha Lee JihaRheum ( View Tweet)
Good performance of #definite
#antisynthetase #syndrome
✅+antibody mandatory
Possible also does ok
@RheumNow #EULAR2026
June 6 #antisynthetase #classifiaction #criteria https://t.co/5sxogTX9YT
Links:
Janet Pope Janetbirdope ( View Tweet)
Steroid use remain common in rheumatology, despite risks even low-dose, especially for older adults.
"Steroids and Me" (Sam) provides online patient education ~5 minutes.
@RheumNow #EULAR2026 POS1388
Jiha Lee JihaRheum ( View Tweet)
Dr. Cavagna presents the 2025 EULAR/ACR Classification Criteria for Anti-Synthetase Syndrome
He emphasizes the inportance of ruling out anti-MDA5 Ab & anti-PM/Scl Ab DM since these conditions share overlapping features w/ ASyS.
@RheumNow #EULAR2026 https://t.co/AtGRlp5qyW
Links:
sheila RHEUMarampa ( View Tweet)
#OP0159 #EULAR2026
Multimodal study in D2T RA identified altered brain connectivity patterns linked to pain, psychological features & peripheral transcriptomics. Supports neuroimmune component in D2T RA & need for personalised approaches beyond inflammation control. @RheumNow https://t.co/qMQbkiMCwX
Mrinalini Dey DrMiniDey ( View Tweet)
